These results provide evidence that targeting USP24-Mcl-1 axis may represent a novel strategy in the treatment of T-ALL and WP1130 is a promising lead compound for developing anti-T-ALL drugs. The gene discussed is MCL1; the disease is acute lymphoblastic leukemia.